Genetic biomarkers of placebo response: what could it mean for future trial design? - Wikidata - wikimedia - TriplyDB

Genetic biomarkers of placebo response: what could it mean for future trial design?

Genetic biomarkers of placebo response: what could it mean for future trial design?

http://www.wikidata.org/entity/Q39347818

about

Catechol-O-methyltransferase Val158Met polymorphism is associated with somatosensory amplification and nocebo responses Understanding placebo and nocebo responses for pain management.Placebo analgesia: understanding the mechanisms.Unanticipated Insights into Biomedicine from the Study of Acupuncture Genetics and the placebo effect: the placebome.Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology.The Clinical Inadequacy of the Placebo Model and the Development of an Alternative Conceptual Framework.Creating placebo responders and nonresponders in the laboratory: boons and banes.

P2860

Q28542991-BC0ECC06-FAEA-4219-B4AF-9E05824592E7 Q34081833-08C149A0-97B8-4584-9739-E628D32CA228 Q35297961-505E1BD3-ABAA-465C-B41D-21DA8EE24312 Q36601924-E0BC62DC-144D-4293-B395-0CBF721C00FF Q38425277-E01CFE61-540F-44F3-9A5C-EE02B1113B3A Q39010517-98B2A641-D08F-451E-A79A-160230B74B22 Q47616648-215C14D5-69F0-4DB3-8453-3C43C26A219B Q50653849-D254CB4F-432C-469E-A905-77951D721D44

P2860

Genetic biomarkers of placebo response: what could it mean for future trial design?

http://www.wikidata.org/entity/Q39347818

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Genetic biomarkers of placebo response: what could it mean for future trial design?

@en

Genetic biomarkers of placebo response: what could it mean for future trial design?

@nl

type

label

Genetic biomarkers of placebo response: what could it mean for future trial design?

@en

Genetic biomarkers of placebo response: what could it mean for future trial design?

@nl

prefLabel

Genetic biomarkers of placebo response: what could it mean for future trial design?

@en

Genetic biomarkers of placebo response: what could it mean for future trial design?

@nl

P1433

Q39347818-1B19BA84-0E5C-4C85-A082-22BE0D834F31

P1476

Q39347818-C0A98D81-E79F-49BE-B06D-AC1BE25BA57B

P2093

Q39347818-1BDABE30-4D00-47F5-9D43-34B32E477588

P2860

Q39347818-0AB96F97-FBE8-475F-BB1B-756A6ADD66CB

Q39347818-1EEF7868-BB05-4E91-AC5D-EDF06C53F8FA

Q39347818-26E61B27-6FF1-4D44-BE3E-94C3470167BA

Q39347818-3E1195E8-B7F4-4850-8E01-F4D86A79C982

Q39347818-47C5966B-8428-4468-ABB3-FBAD029DA353

Q39347818-4B8AEA40-F41B-4DFC-A514-230CC43F24DE

Q39347818-4DAB1E65-5FF7-43F9-881D-65F514D464D2

Q39347818-60F62065-EA93-44AE-8F56-0D7D5B1336EE

Q39347818-60F70B26-8CC6-48DF-9A50-97E1ADEABDEA

Q39347818-6447AA28-B3D7-44E2-98C2-30C075053BE8

P304

Q39347818-AB09A0D6-D060-4A32-9EF4-F33276BCEB92

P31

Q39347818-118A90E6-4E94-44B2-A6E8-D2D803DDE573

P356

Q39347818-4AF61CBE-8DDF-4DCF-B16D-128128A49990

P433

Q39347818-7AF6172D-33D0-4333-8986-4AD64AEC7855

P478

Q39347818-8FB7ED87-436F-446A-9C80-DE07A52151A7

P50

Q39347818-13540763-A5A6-46F5-82CC-4454652E9FA9

P577

Q39347818-6E7B4547-5CEB-4351-AAE5-7DA95285842F

P5875

Q39347818-92399127-63E6-43DE-9DD0-21361A1B14DA

P698

Q39347818-00D6A2F6-D5D1-44B2-8281-DB245325614F

P921

Q39347818-58B71492-F6AD-4406-9F22-D2675D186C1F

Q39347818-D275EFFF-22B8-4E23-A132-70807D23BF34

P932

Q39347818-B530C9DF-85D0-4901-A853-A0DDE0F51852

P356

P1433

Clinical investigation

P1476

Genetic biomarkers of placebo response: what could it mean for future trial design?

@en

P2093

Kathryn T Hall

http://www.w3.org/2001/XMLSchema#string

P2860

Catechol-O-methyltransferase val158met polymorphism predicts placebo effect in irritable bowel syndrome

Neurobiological mechanisms of placebo responses

Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues

Monoamine oxidase a and catechol-o-methyltransferase functional polymorphisms and the placebo response in major depressive disorder

Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.

The placebo effect in Parkinson's disease.

The mechanism of placebo analgesia.

Tolcapone improves cognition and cortical information processing in normal human subjects.

The biochemical and neuroendocrine bases of the hyperalgesic nocebo effect.

Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme.

P304

311-314

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4155/CLI.13.8

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256765213

http://www.w3.org/2001/XMLSchema#string

P698

24049631

http://www.w3.org/2001/XMLSchema#string

P921

P932

3774308

http://www.w3.org/2001/XMLSchema#string